Cooperative Cardiovascular Project (CCP) Quality Improvement in Maine,New Hampshire,and Vermont

Abstract

The Cooperative Cardiovascular Project (CCP) is a nationwide quality improvement project (quality indicator measurement, feedback, remeasurement) in Medicare acute myocardial infarction (AMI) patients sponsored by the Health Care Financing Administration (HCFA). In Maine, New Hampshire, and Vermont, 3,472 baseline records were abstracted from 76 hospitals from January 1994 to February 1995. After feedback, 2,270 remeasurements were collected from October 1996 to May 1997. At remeasurement, performance improved significantly for "ideal" candidates (defined by the CCP) on five quality indicators-aspirin during hospitalization 88% to 93% (p < .001), thrombolytic timing 60% to 69% (p <.01), discharge aspirin 83% to 90% (p < .001), discharge beta-blockers 69% to 82% (p < .01), and calcium channel blocker avoidance 83% to 93% (p < .05). Reperfusion, angiotensin converting enzyme inhibitors, and smoking cessation advice did not improve significantly. This study demonstrates that evidence-based indicators, nationally designed data collection, and locally based interventions can significantly improve AMI care.

Get full access to this article

View all access options for this article.

References

Ambrosioni, E. , Borghi, C. , & Magnani, B. (1995). The effect of the angiotensin converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction: The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. New England Journal of Medicine, 332, 80-85.

Antiplatelet Trialists' Collaboration . (1988). Secondary prevention of vascular disease by prolonged antiplatelet treatment: Antiplatelet Trialists' Collaboration. British Medical Journal, 296, 320-331.

Barry, J. , Mead, K. , Nabel, E. G. , Rocco, M. B. , Campbell, S. , Fenton, T. , Mudge, G. H. Jr. , & Selwyn, A. P. (1989). Effect of smoking on the activity of ischemic heart disease. Journal of the American Medical Association, 261, 398-402.

Cairns, J. A. , & Markham, B. A. (1995). Economics and efficacy in choosing oral anticoagulants or aspirin after myocardial infarction. Journal of the American Medical Association, 273, 965-967.

Cannon, C. P. , & Braunwald, E. (1996). Time to reperfusion: The critical modulator in thrombolytic and primary angioplasty. Journal of Thrombosis and Thrombolysis, 3,109-117.

Dicker, R. C. , Ordin, D. L. , Han, L. F. , & Campbell, M. K. (1997). Introducing the Medicare quality of care surveillance system. Quality resume (No. 1). Baltimore: Health Care Financing Administration.

Ellerbeck, E. F. , Jencks, S. F. , Radford, M. J. , Kresowik, T. F. , Craig, A. S. , Gold, J. A. , Krumholz, H. M. , & Vogel, R. A. (1995). Quality of care for Medicare patients with acute myocardial infarction: A four-state pilot study from the Cooperative Cardiovascular Project. Journal of the American Medical Association, 273, 1509-1514.

Every, N. R. , Parsons, L. S. , Hlatky, M. , Martin, J. S. , & Weaver, W. D. (1996). A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction: Myocardial Infarction Triage and Intervention Investigators. New England Journal of Medicine, 335, 1253-1260.

Fibrinolytic Therapy Trialists' (FTT) Collaborative Group . (1994). Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomized trials of more that 1000 patients. Lancet, 343,311-322.

10.

First International Study of Infarct Survival Collaborative Group . (1986). Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS-I. Lancet, 2, 57-66.

11.

Furberg, C. D. , Psaty, B. M. , & Mayer, J. V. (1995). Nifedipine: Dose-related increase in mortality in patients with coronary heart disease. Circulation, 92, 1326-1331.

12.

Fuster, V. , Dyken, M. L. , Vokonas, P. S. , & Hennekens, C. (1993). Aspirin as a therapeutic agent in cardiovascular disease. Circulation, 87, 659-675.

13.

Gibbons, R. J. , Holmes, D. R. , Reeder, G. S. , Bailey, K. R. , Hopfenspirger, M. R. , & Gersh, B. J. (1993). Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction: The Mayo Coronary Care Unit and Catheterization Laboratory Groups. New England Journal of Medicine, 328, 685-691.

14.

Gunnar, R. M. , Passamani, E. R. , Bourdillon, P. D. , Pitt, B. , Dixon, D. W. , Rapaport, E. , Fuster, V. , Reeves, T. J. , Karp, R. B. , Russell, R. O. Jr. , Kennedy, J. W. , Klocke, F. J. , Sobel, B. E. , & Winters, W. L. Jr. (1990). Guidelines for the early management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures. Journal of the American College of Cardiology, 16, 249-292.

15.

Houston-Miller, N. , & Taylor, C. B. (1995). Lifestyle management for patients with coronary heart disease. Champaign, IL: Human Kinetics.

16.

Huff, E. D. (1997). Comprehensive reliability assessment and comparison of quality indicators and their components. Journal of Clinical Epidemiology, 50, 1395-1404.

17.

ISIS-2 (Second International Study of Infarct Survival) Collaborative Group . (1988). Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Journal of the American College of Cardiology, 12(Suppl. A), 3A-13A.

18.

Jencks, S. F. , & Wilensky, G. R. (1992). The Health Care Quality Improvement Initiative: Anew approach to quality assurance in Medicare. Journal of the American Medical Association, 268,900-903.

19.

Kleiman, N. S. , White, H. D. , Ohman, E. M. , Ross, A. M. , Woodlief, L. H. , Califf, R. M. , Holmes, D. R. Jr. , Bates, E. , Pfisterer, M. , Vahanian, A. , & Topol, EJ. , forthe GUSTO Investigators . (1994). Mortality within 24 hours of thrombolysis for myocardial infarction: The importance of early reperfusion. The GUSTO investigators, global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries. Circulation, 90, 2658-2665.

20.

Koren, G. , Weiss, A. T. , Hasin, Y. , Appelbaum, D. , Welber, S. , Rozenman, Y. , Lotan, C. , Mosseri, M. , Sapoznikov, D. , Luria, M. H. , & Gotsman, M. S. (1985). Prevention of myocardial damage in acute myocardial ischemia by early treatment with intravenous streptokinase. New England Journal of Medicine 313, 1384-1389.

21.

Lambert-Huber, D. A. , Ellerbeck, E. F. , Wallace, R. G. , Radford, M. J. , Kresowik, T. F. , & Allison, J. A. (1994). Quality of care indicators for patients with acute myocardial infarction: Pilot validation of the indicators. Clinical Performance and Quality Health Care, 2, 219-222.

22.

Latini, R. , Maggioni, A. P. , Flather, M. , Sleight, P. , & Tognoni, G. (1995). ACE inhibitor use in patients with myocardial infarction: Summary of evidence from clinical trials. Circulation, 92, 3132-3137.

23.

Marciniak, T. A. , Ellerbeck, E. F. , Radford, M. J. , Kresowik, T. F. , Gold, J. A. , Krumholz, H. M. , Kiefe, C .I. , Allman, R. M. , Vogel, R. A. , & Jencks, S. F. (1998). Improving the quality of care for Medicare patients with acute myocardial infarction: Results from the Cooperative Cardiovascular Project pilot. Journal of the American Medical Association, 279, 1351-1357.

24.

MIAMI Trial Research Group . (1985). Metoprolol in acute myocardial infarction: Patient and methods. American Journal of Cardiology, 56, 3G-9G.

25.

Muller, J. E. , Morrison, J. , Stone, P. H. , Rude, R. E. , Rosner, B. , Roberts, R. , Pearle, D. L. , Turi, Z. G. , Schneider, J. F. , Serfas, D. H. , Tate, C. , Scheiner, E. J. , Sobel, B. E. , Hennekens, C. H. , & Braunwald, E. (1984). Nifedipine therapy for patients with threatened and acute myocardial infarction: A randomized, double-blind, placebo-controlled comparison. Circulation, 69,740-747.

26.

National Heart, Lung, and Blood Institute . (1992). Morbidity and mortality: Chart book on cardiovascular, lung, and blood diseases. Bethesda, MD: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health.

27.

National Heart, Lung, and Blood Institute . (1994a). 9-1-1: Rapid identification and treatment of acute myocardial infarction. National Heart Attack Alert Program (NHAAP). NIH Publication 94-3302. Bethesda, MD: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health.

28.

National Heart, Lung, and Blood Institute . (1994b). Patient/bystander recognition and action. Rapid identification and treatment of myocardial infarction. National Heart Attack Alert Program (NHAAP), NIH Publication 94-3303. Bethesda, MD: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health.

29.

Pfeffer, M. A. , Braunwald, E. , Moye, L. A. , Basta, L. , Brown, E. J. Jr. , Cuddy, T. E. , Davis, B. R. , Geltman, E. M. , Goldman, S. , Flaker, G. C. , Klein, M. , Lamas, G. A. , Packer, M. , Rouleau, J. , Rouleau, J. L. , Rutherford, J. , Wertheimer, J. H. , & Hawkins, C. M. (1992). Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the survival and ventricular enlargement trial-the SAVE Investigators. New England Journal of Medicine, 327,669-677.

30.

Roux, S. , Christeller, S. , & Ludin, E. (1992). Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: Ameta-analysis. Journal of the American College of Cardiology, 19,671-677.

31.

Ryan, T. J. , Anderson, J. L. , Antman, E. M. , Braniff, B. A. , Brooks, N. H. , Califf, R. M. , Hillis, L. D. , Hiratzka, L. F. , Rapaport, E. , Riegel, B. J. , Russell, R. O. , Smith, E. E. III , & Weaver, W. D. (1996). ACCI/AHA guidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Journal of the American College of Cardiology, 28, 1328-1428.

32.

Ryan, T. J. , Bauman, W. B. , Kennedy, J. W. , Kereiakes, D. J. , King, S.B. III , McCallister, B. D. , Smith, S. C. Jr. , & Ullyot, D. J. (1993). ACC/AHA guidelines forpercutaneous transluminal coronary angioplasty: A report of the American Heart Association/American College of Cardiology Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Percutaneous Transluminal Coronary Angioplasty). Circulation, 88, 2987-3007.

33.

TIMI Study Group . (1989). Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: Results of the thrombolysis in myocardial infarction (MIMI) Phase II trial. New England Journal of Medicine, 320,618-627.

34.

Yusuf, S. , Peto, R. , Lewis, J. , Collins. R. , & Sleight, P. (1985). Beta blockade during and after myocardial infarction: An overview of the randomised trials. Progress in Cardiovascular Diseases, 27, 335-371.